|
1
|
Hickford ES, O'Connell J, Maloney A, Florian P, Johnston GI, Rospo CC, Herrmann M, Wright S, Bourne T. Target occupancy biomarker assay development using a conformation-selective antibody against small-molecule-bound TNF. Bioanalysis 2023; 15:343-359. [PMID: 37026566 DOI: 10.4155/bio-2022-0231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/08/2023] Open
Abstract
Background: An antibody specific to small-molecule inhibitor-bound TNF has enabled the development of target occupancy biomarker assays to support the development of novel treatments for autoimmune disorders. Materials & methods: ELISAs were developed for inhibitor-bound and total TNF to determine the percentage of TNF occupancy in samples from stimulated blood. Inhibitor-saturated samples allowed measurement of total and inhibitor-bound TNF in a single electrochemiluminescence immunoassay. Results: TNF occupancy was proportional to inhibitor concentration in plasma samples. An electrochemiluminescence method for inhibitor-bound TNF was validated for use as a potential clinical occupancy biomarker assay. Conclusion: Development of these assays has allowed measurement of a target occupancy biomarker, which has supported progression of the first small-molecule inhibitors of TNF.
Collapse
Affiliation(s)
| | - James O'Connell
- Early Solutions, UCB Biopharma UK, 208 Bath Road, Slough, SL1 3WE, UK
| | - Alison Maloney
- Early Solutions, UCB Biopharma UK, 208 Bath Road, Slough, SL1 3WE, UK
| | - Peter Florian
- Type 1/17 Cluster, Immunology & Inflammation Research TA, Sanofi R&D, Frankfurt, 65926, Germany
| | | | - Chiara Carla Rospo
- Early Solutions, UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium
| | - Matthias Herrmann
- Type 1/17 Cluster, Immunology & Inflammation Research TA, Sanofi R&D, Frankfurt, 65926, Germany
| | - Sara Wright
- Early Solutions, UCB Biopharma UK, 208 Bath Road, Slough, SL1 3WE, UK
| | - Tim Bourne
- Early Solutions, UCB Biopharma UK, 208 Bath Road, Slough, SL1 3WE, UK
| |
Collapse
|
|
2
|
Delaunois A, Betat AM, Colomar A, Rospo CC, Staelens L, Delpy E, Rochelle CDL. Is the telemetered guinea pig a suitable model to detect PR interval and QRS changes? J Pharmacol Toxicol Methods 2014. [DOI: 10.1016/j.vascn.2014.03.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
|
3
|
Delpy E, Parachou D, Deal A, Fonsi M, Rospo CC, Staelens L, Delaunois A, La Rochelle CD. Refinement of the PTZ infusion seizure test in the rat by evaluation of plasma concentrations of PTZ and test compound. J Pharmacol Toxicol Methods 2013. [DOI: 10.1016/j.vascn.2013.01.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|